Cargando…
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
PURPOSE: This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. METHODS: Five cohorts of three patients received i.v. ascorbic acid admi...
Autores principales: | Stephenson, Christopher M., Levin, Robert D., Spector, Thomas, Lis, Christopher G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691494/ https://www.ncbi.nlm.nih.gov/pubmed/23670640 http://dx.doi.org/10.1007/s00280-013-2179-9 |
Ejemplares similares
-
Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis
por: Fowler, Alpha A, et al.
Publicado: (2014) -
Pharmacokinetics of intravenous administered two different high doses of ascorbic acid in healthy beagle dogs
por: Lim, Seula, et al.
Publicado: (2019) -
Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019) -
Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018) -
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
por: Doi, Toshihiko, et al.
Publicado: (2020)